Key terms
About KZR
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest KZR news
Mar 25
8:20am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kezar Life Sciences (KZR), Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Cue Health (HLTH)
Mar 14
4:03pm ET
Kezar Life Sciences reports Q4 EPS (44c), consensus (38c)
Feb 27
6:28am ET
Buy Rating Affirmed for Kezar Life Sciences Amidst Progress in Lupus Nephritis Treatment and Expansion into Chinese Market
Feb 26
6:13pm ET
Everest Medicines, Kezar Life Sciences get China IND approval for PALIZADE trial
No recent press releases are available for KZR
KZR Financials
Key terms
Ad Feedback
KZR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
KZR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
